Advertisement.
Advertisement.
Advertisement
Advertisement.
CTXR Citius Pharmaceuticals Inc
22,205
| Market Cap | $173.45M |
| Volume | 1.04M |
| 52-Wk High | $1.07 |
| 52-Wk Low | $0.48 |
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
PR Newswire•17 days ago
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July 10, 2024...
Share to Feed
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results...
PR Newswire•2 months ago
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial...
PR Newswire•2 months ago
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and...
PR Newswire•2 months ago
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor...
PR Newswire•3 months ago
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April...
PR Newswire•3 months ago
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 26, 2024 CRANFORD...
PR Newswire•3 months ago
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma Citius Pharmaceuticals Announces Addition of...
PR Newswire•4 months ago
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire CRANFORD...
PR Newswire•4 months ago
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius...
PR Newswire•4 months ago